Global anti-infectives market share by geography, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Sales of types of anti-infectives brands, 2004-5

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Competitive dynamics of the drug classes in the global anti-infectives
market, 2004-5

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Competitive dynamics of the drug classes in the global anti-infectives
market, 2004-5

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Competitive dynamics of the leading anti-viral treatments in the global
anti-infectives market, 2004-5

From: The Global Anti-Infectives Market Outlook to 2011. Source: Bubble size represents 2005 market share Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Competitive dynamics of the leading vaccines in the global anti-
infectives market, 2004-5

From: The Global Anti-Infectives Market Outlook to 2011. Source: Bubble size represents 2005 market share Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Competitive dynamics of the global anti-bacterial market by drug class,
2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: IMS Health; Business Insights
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Competitive dynamics of the ten leading brands in the anti-bacterial
drug class, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: IMS Health; Business Insights
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Competitive dynamics of the ten leading brands in the anti-fungal drug
class, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: IMS Health; Business Insights
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Prevailing R&D approaches, 2006

From: The Global Anti-Infectives Market Outlook to 2011. Source: Author’s research and analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 The anti-infectives pipeline by indication and stage of development,
2006

From: The Global Anti-Infectives Market Outlook to 2011. Source: Author’s research and analysis
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Leading recently launched products and late-stage R&D in the anti-
infectives market, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Author’s research and analysis, company reports
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Competitive dynamics of the leading players in the global anti-infectives
market, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 GSK’s anti-infectives sales, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Pfizer’s anti-infectives sales, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Novartis’ anti-infectives sales, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Sanofi-Aventis’ anti-infectives sales, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Merck’s anti-infectives sales, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Johnson & Johnson anti-infectives sales, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Roche’s anti-infectives sales, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Wyeth’s anti-infectives sales, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Abbott’s anti-infectives sales, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007
 Schering-Plough’s anti-infectives sales, 2005

From: The Global Anti-Infectives Market Outlook to 2011. Source: Business Insights; IMS
Created for Global User, Novartis- Global License. IP Address: 160.62.4.10
© Business Insights Limited, 2007